

DEPARTMENT OF DEFENSE

Defense Health Agency

Intent to Grant an Exclusive License for U.S. Government Owned Invention

AGENCY: Defense Health Agency, DoD.

ACTION: Notice.

SUMMARY: In accordance with applicable laws and regulations, announcement is made of the intent to grant an exclusive, royalty-bearing, revocable, license within a field of use.

ADDRESSES: Commander, U.S. Army Medical Research and Development Command,
ATTN: Director, Office of Research and Technology Applications, 1520 Freedman Drive, Suite
227, Fort Detrick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: Dr. David Humphrey, Office of Research &
Technology Applications, (301) 619-6975. For patent issues, Ms. Leigh Callander, Supervisory
Patent Attorney, (301) 619-7808.

SUPPLEMENTARY INFORMATION: In accordance with 35 U.S.C. 209 (e) and 37 CFR
404.7 (a)(1)(i), announcement is made of the intent to grant an exclusive within a field of use,
royalty-bearing, revocable license agreement to U.S. Patent Application 18/881,793 and
European Patent Application 2384370.4 entitled “Monoclonal Antibodies that Interfere with Iron
Uptake” to Triari Pharmaceuticals Inc., having its principal place of business at 99 Main Street,
B308, Hartford, Connecticut 06106.

Anyone wishing to object to grant of this option can file written objections along with
supporting evidence, if any, within 15 days from the date of this publication. Written objections

are to be filed with the Director, Office of Research and Technology Applications (see **ADDRESSES**).